| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Product containing phenyltoloxamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing clemastine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing calcium channel blocker (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Class I antiarrhythmic drug |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Class Ia antiarrhythmic drug |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing alpha adrenergic receptor antagonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Medicinal product acting as antiarrhythmic agent (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Class II antiarrhythmic drug |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing bromazine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing alpha-1 adrenergic receptor antagonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Class III antiarrhythmic drug |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Class Ib antiarrhythmic drug |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing diphenylpyraline (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Class Ic antiarrhythmic drug |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing carbinoxamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing clemastine fumarate and paracetamol and phenylpropanolamine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely clemastine fumarate 335 microgram and paracetamol 500 milligram and phenylpropanolamine 30 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely trimethobenzamide hydrochloride 300 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to drug primarily affecting the cardiovascular system NOS |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Individual arrhythmias [no drugs here] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Drug for supraventricular arrhythmia |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Drug for ventricular arrhythmia |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Diphenylpyraline hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing magnesium salicylate and phenyltoloxamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Ethanolamine oleate 5% injection solution 2 mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Ethanolamine oleate 5% injection solution 5 mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing trimethobenzamide hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Cardiac adrenergic blocking product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Anesthetic antiarrhythmic agent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Bromodiphenhydramine+codeine 12.5mg/5mL/10 mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+dextromethorphan hydrobromide+pseudoephedrine hydrochloride 4mg/5mL/15mg/5mL/60mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+dextromethorphan hydrobromide+pseudoephedrine hydrochloride 2mg/1mL/4mg/1mL/25mg/1mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+dextromethorphan hydrobromide+pseudoephedrine hydrochloride 2mg/1mL/4mg/1mL/15mg/1mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+pseudoephedrine hydrochloride 4mg/5mL/60mg/5mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+pseudoephedrine hydrochloride 2mg/1mL/15mg/1mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+pseudoephedrine hydrochloride 2mg/1mL/25mg/1mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+pseudoephedrine hydrochloride 2mg/5mL/30mg/5mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate 4 mg and pseudoephedrine hydrochloride 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate 4 mg and pseudoephedrine hydrochloride 60 mg chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+pseudoephedrine hydrochloride 8mg/120mg m/r tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Clemastine fumarate 0.67mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Clemastine fumarate 2.68 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Ethanolamine oleate 50mg/mL injection 2mL ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Chlorpheniramine maleate+phenylephrine hydrochloride+phenyltoloxamine citrate 4mg/20mg/50mg m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Chlorpheniramine maleate+phenylephrine hydrochloride+phenyltoloxamine citrate 2.5mg/5mL 5mg/5mL 7.5mg/5mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely trimethobenzamide hydrochloride 250 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely trimethobenzamide hydrochloride 100 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Trimethobenzamide hydrochloride 100 mg/2% suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Trimethobenzamide hydrochloride 200 mg/2% suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Trimethobenzamide hydrochloride 100 mg/mL intramuscular solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate 2mg/5mL liquid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Trimethobenzamide hydrochloride 100mg/mL injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Trimethobenzamide hydrochloride 200mg suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Trimethobenzamide hydrochloride 100mg suppositories |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Trimethobenzamide hydrochloride 100mg/mL bar |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Nonspecific alpha-adrenergic blocking product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely paracetamol 300 milligram and phenyltoloxamine citrate 20 milligram and salicylamide 200 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Paracetamol 300 mg and phenyltoloxamine citrate 20 mg and salicylamide 200 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Acetaminophen + phenyltoloxamine citrate 500mg/30mg caplets |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Paracetamol 500 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Paracetamol 500 mg and phenyltoloxamine citrate 60 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Paracetamol 650 mg and phenyltoloxamine citrate 50 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Benzocaine + trimethobenzamide hydrochlor 2%ww/100mg suppositories |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Benzocaine 20 microgram and trimethobenzamide hydrochloride 200 mg rectal suppository |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely clemastine 1.34 milligram and phenylpropanolamine 75 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+dextromethorphan hydrobromide+pseudoephedrine hydrochloride 4mg/5mL/12.5mg/5mL/60mg/5mL syrup |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+dextromethorphan hydrobromide+pseudoephedrine hydrochloride 1mg/1mL/4mg/1mL/15mg/1mL drop |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+pseudoephedrine hydrochloride 1mg/1mL/15mg/1mL drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| [X]Lipid-lowering drug adverse reaction |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| [X]Statin causing adverse effect in therapeutic use |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing paracetamol and phenyltoloxamine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Carbinoxamine maleate+dextromethorphan hydrobromide+pseudoephedrine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing benzocaine and trimethobenzamide hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Chlorpheniramine maleate+phenylephrine hydrochloride+phenyltoloxamine citrate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing paracetamol and phenyltoloxamine citrate and salicylamide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing bromazine and codeine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing carbinoxamine maleate and pseudoephedrine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| [X]Angiotensin II receptor antagonists causing adverse effects in therapeutic use |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely clemastine 1.34 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Adenosine A2 receptor agonist |
Is a |
True |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
|
| Cardioversion using medication (procedure) |
Using substance (attribute) |
True |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
1 |
| Drug groups primarily affecting the cardiovascular system allergy |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
1 |
| Spironolactone adverse reaction (disorder) |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Spironolactone and thiazide diuretic adverse reaction |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
3 |
| Cyclopenthiazide adverse reaction |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Intentional frusemide poisoning |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
1 |
| Allergy to mersalyl |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Accidental acetazolamide poisoning |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
1 |
| Allergy to hydrochlorothiazide |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Poisoning caused by diuretic |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Allergy to triamterene |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Allergy to amiloride and thiazide diuretic |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
3 |
| Allergy to piretanide (finding) |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Amiloride and loop diuretic adverse reaction |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
3 |
| Mannitol adverse reaction |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Mefruside adverse reaction |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Allergy to acetazolamide (finding) |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Poisoning by acetazolamide |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Frusemide poisoning of undetermined intent |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Mercaptomerin poisoning |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
| Indapamide adverse reaction |
Causative agent (attribute) |
False |
Cardiovascular agent (substance) |
Inferred relationship |
Some |
2 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]